Form 4: Lantern Pharma Director Acquires Stock Options
SEC Form 4 Filing
Maria-Luisa Maccecchini, a director at Lantern Pharma Inc., acquired stock options on July 15, 2024.
Summary
- On July 15, 2024, Maria-Luisa Maccecchini, a director of Lantern Pharma Inc. (LTRN), acquired 5,000 stock options.
- The options have an exercise price of $4.35.
- The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
- The options will vest in equal monthly increments over a 36-month period, starting August 15, 2024.
- The options expire on July 15, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 07/15/2024 | Date of transaction: Director acquired stock options. |
| 08/15/2024 | Vesting of options begins in equal monthly increments over 36 months. |
| 07/15/2034 | Expiration date of the stock options. |
| 07/17/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.